Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection Patent Expiration

Exclusivity Information

Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection's exclusivity codes and their expiration dates are given below.

Drug Exclusivity Drug Exclusivity Expiration
NCI Jun 04, 2027

About Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection

Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection is a drug owned by SPARHAWK LABORATORIES, INC. Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection uses Iron Dextran Complex as the active ingredient.

Active Ingredient:

Iron Hydrogenated Dextran Injection Iron Dextran 20 Injection uses Iron Dextran Complex as the active ingredient. Check out other Drugs and Companies using Iron Dextran Complex ingredient.